Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
NewAmsterdam Pharma Company NV - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
NAMS
Nasdaq
2836
https://ir.newamsterdampharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for NewAmsterdam Pharma Company NV
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
- Mar 25th, 2024 12:00 pm
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
- Mar 12th, 2024 12:00 pm
NewAmsterdam Pharma Full Year 2023 Earnings: Revenues Miss Expectations
- Mar 1st, 2024 10:14 am
NewAmsterdam Pharma Co NV (NAMS) Faces Net Loss in 2023 Despite Clinical Progress
- Feb 28th, 2024 1:33 pm
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
- Feb 28th, 2024 1:00 pm
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
- Feb 26th, 2024 1:00 pm
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
- Feb 14th, 2024 3:40 am
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
- Feb 13th, 2024 9:01 pm
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Feb 1st, 2024 9:01 pm
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
- Jan 8th, 2024 1:00 pm
NewAmsterdam Pharma Announces 2024 Strategic Priorities
- Jan 4th, 2024 1:00 pm
Institutions own 18% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) shares but private equity firms control 52% of the company
- Jan 1st, 2024 12:03 pm
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
- Nov 13th, 2023 1:00 pm
RBC initiates coverage of NewAmsterdam on CETP inhibitor
- Oct 31st, 2023 4:05 pm
AbbVie upgraded, Cisco downgraded: Wall Street's top analyst calls
- Oct 30th, 2023 1:43 pm
NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer
- Oct 23rd, 2023 12:00 pm
NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation
- Sep 21st, 2023 11:00 am
NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
- Sep 20th, 2023 12:00 pm
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
- Aug 14th, 2023 8:01 pm
NewAmsterdam Pharma First Half 2023 Earnings: €0.92 loss per share (vs €1.50 profit in 1H 2022)
- Aug 10th, 2023 10:01 am
Scroll